April 12, 2017
Respira Therapeutics, United Therapeutics Corporation join to fight pulmonary hypertension
Respira Therapeutics, a privately held pharmaceutical company developing innovative inhaled therapies to treat pulmonary hypertension and other pulmonary diseases, has entered into a strategic collaboration with United Therapeutics Corporation for the development and exclusive license of Respira’s inhaled drug-device product, RT234, for pulmonary hypertension indications in North America.